2023 Annual Meeting Poster Awardee Spotlight: Stan and Moravčík
Date: May 16, 2024 Time: 8am PDT / 11am EDT / 5pm CEST Title: Validation lab: allowing standardized in vitro and in vivo experiments for candidate treatments for Duchenne muscular dystrophy Description: The Validation Lab was established in 2015 with support ...
In-silico siRNA Off-Target Predictions: What Should We Be Looking For?
Date: May 2, 2024 Time: 8am PDT / 11am EDT / 5pm CEST Title: In-silico siRNA Off-Target Predictions: What Should We Be Looking For? Description: Assessing sequence-dependent off-target risks is a critical step during siRNA development to ensure the safety and ...
In vivo Optical Control of Gene-Silencing in Japanese Medaka Fish Embryos
Time: 8am PDT / 11am EDT / 5pm CEST Date: April 25, 2024 Title: In vivo Optical Control of Gene-Silencing in Japanese Medaka Fish Embryos Description: The siRNA oligonucleotide duplex inherent to biology, functions by binding and cleaving mRNA, a process ...
RNA Targeting Technology – Chemistry and Delivery
Time: 8am PDT / 11am EDT / 4pm CET Date: March 21, 2024 Title: RNA Targeting Technology – Chemistry and Delivery Description: Chemistry coupled with pharmacology, both preclinical and clinical, forms the basis for the pipeline we manage at Ionis today. ...
2023 Annual Meeting Poster Awardee Spotlight
Time: 8AM PST | 11AM EST | 5PM CET Date: February 29, 2024 Title: Towards Allele-Selective Gapmer ASO Design Description: Allele selective gapmer antisense oligonucleotides (ASOs) are a promising strategy for the treatment of rare monogenic neurodevelopmental disorders caused by gain-of-function or ...
Meet OTS’ New BOD Trainee Reps
Time: 8AM PST | 11AM EST | 5PM CET Date: February 22, 2024 Title: Advancing Therapeutic Approaches for Erythropoietic Protoporphyria Description: Currently, no curative treatment is available for the rare disease erythropoietic protoporphyria (EPP). The genetic background of EPP is well ...
2023 Annual Meeting Poster Awardee Spotlight
Time: 8AM PST | 11AM EST | 5PM CET Date: January 25, 2024 Title: siRNA therapy for ex vivo treatment of stem cell grafts and/or donor lymphocytes Description: Allogeneic T cells represent the most potent treatment for hematopoietic malignancies such es ...
Non-viral DNA delivery: Opportunities and challenges
Time: 8AM PST | 11AM EST | 5PM CET Date: October 12, 2023 This presentation will cover defining the key hurdles for non-viral DNA delivery, innate immune stimulation, and delivery to post-mitotic nuclei, as well as strategies to address these challenges. ...
ASO activity and distribution after LNP delivery
Time: 8AM PST | 11AM EST | 5PM CET Date: Thursday, September 14, 2023 Webinar title: Assessing antisense oligonucleotide delivery to the brain What is your research about? Amy Byrnes, PhD, focuses her research on understanding how delivery vehicles impact antisense oligonucleotide (ASO) ...
Muscle targeted siRNA Conjugates for Pompe Disease
Time: 8AM PST / 11AM EST / 5PM CET Date: August 3, 2023 Aro Biotx is focused on developing Centyrin-siRNA conjugates for treatment of extrahepatic genetic diseases. Our lead program employs a CD71 Centyrin for targeting to muscle together with an siRNA for ...
